All In MedTech

FDA Clearance Tracker · P100014-S026

Solesta Injectable Gel

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 9, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 9, 2020

Approved

Time to decision

175 days

Received Apr 17, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P100014-S026
Device name
Solesta Injectable Gel
Applicant location
Santa Barbara, CA
Received
Apr 17, 2020
Decided
Oct 9, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P100014

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

Approval of labeling changes after the final report for the post-approval study (PAS) protocol.

Source documents

Other decisions for Palette Life Sciences

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.